AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 21- 52-wk high
- $30.05
- 52-wk low
- $12.07
- Prev close
- $19.74
- Mkt cap
- $10.46B
- Fwd P/E
- 3.7x
- Beta
- -1.24
Smart money
Earnings
Earnings came in 7.7% below what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Jun 2026
| USD | Sep 2025 | Jun 2026 |
|---|---|---|
| What came in | ||
| Revenue | $0 | $0 |
| What it spent | ||
| Research and development | $131.1M | $157.7M |
| Sales and admin | $103.1M | $62.8M |
| Total operating expenses | $234.2M | $220.5M |
| What was left | ||
| Operating profit | -$234.2M | -$220.5M |
| Interest on debt | $0 | — |
| Profit before tax | -$231.8M | -$215.7M |
| Net profit | -$231.8M | -$215.7M |
| EBITDA | — | -$215.7M |
Technicals
Price structure
No data yet
Technicals sync when verified market data is available. No sample data is shown.
News
What the news says
9 articles · 7 days
Coverage leans bullish
Tone of tracked coverage
Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright
Leans bearishAug 18Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low - Here's Why
Leans bearishAug 17Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT
NeutralAug 14
